Posted by KaraS on August 15, 2005, at 22:33:54
In reply to Bad new RE Reminyl, posted by ed_uk on August 13, 2005, at 9:52:49
> Data on Alzheimer’s treatment galantamine (Reminyl) are being reviewed after a preliminary analysis last
> year indicated that three times more patients taking Reminyl died compared to those receiving placebo.
> The studies (GAL-INT-11 and GAL-INT-18) included 2000 patients and were designed to evaluate a
> potential decrease in the rate of progression from mild cognitive impairment to dementia. Overall, there were
> 20 deaths, 15 in the Reminyl group, and five in the placebo-treated group. Johnson & Johnson states that
> "overall mortality rates were low in both the Reminyl and placebo groups compared to this particular
> population or in AD patients." The company is currently analysing additional data from the studies, including
> information retrieved from subjects who had dropped out of the trials, and is discussing the results with
> regulatory authorities.
That's scary. That drug is easily purchased over the Internet too and I would bet that a lot of people take it on their own in order to stay mentally sharp.k
poster:KaraS
thread:541028
URL: http://www.dr-bob.org/babble/20050811/msgs/542237.html